Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii

Drug Resist Updat. 2012 Aug;15(4):237-47. doi: 10.1016/j.drup.2012.06.001. Epub 2012 Jul 27.


The global emergence of multidrug resistance (MDR) among Gram-negative bacteria has dramatically limited the therapeutic options. During the last two decades, Acinetobacter baumannii has become a pathogen of increased clinical importance due to its remarkable ability to cause outbreaks of infections and to acquire resistance to almost all currently used antibiotics, including the carbapenems. This review considers the literature on A. baumannii and data from multilocus sequence typing studies to explore the global population structure of A. baumannii and detect the occurrence of clonality, with the focus on the presence of specific resistance mechanisms such as the OXA-carbapenemases. The worldwide dissemination of MDR and carbapenem non-susceptible A. baumannii is associated with diverse genetic backgrounds, but predominated by a number of extensively distributed clones, such as CC92(B)/CC2(P) and CC109(B)/CC1(P), which have frequently been supplemented by acquired OXA-type carbapenemase genes.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Acinetobacter Infections / microbiology*
  • Acinetobacter baumannii / drug effects
  • Acinetobacter baumannii / enzymology
  • Acinetobacter baumannii / genetics*
  • Animals
  • Bacterial Proteins / genetics
  • Carbapenems / pharmacology*
  • Drug Resistance, Multiple, Bacterial / genetics*
  • Humans
  • Molecular Epidemiology
  • Oxytocin / analogs & derivatives
  • Oxytocin / pharmacology
  • beta-Lactamases / genetics


  • Bacterial Proteins
  • Carbapenems
  • Oxytocin
  • oxytocin, Asp(5)-
  • beta-Lactamases
  • carbapenemase